Chordate Medical Holding AB Logo

Chordate Medical Holding AB

Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.

CMH | ST

Overview

Corporate Details

ISIN(s):
SE0021486131 (+1 more)
LEI:
549300R0GG2J3S0BFN79
Country:
Sweden
Address:
C/O Regus, 164 40 Kista

Description

Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia®, a CE-marked, drug-free neuromodulation treatment. The technology is indicated for the treatment of chronic migraine and chronic rhinitis. Ozilia® provides a non-pharmacological alternative to conventional medications, such as pills or injections, and is associated with minimal side effects. The company's business model is centered on building value through an extensive patent portfolio, clinical studies demonstrating efficacy, and establishing commercial success in selected markets with the goal of a future exit.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chordate Medical Holding AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordate Medical Holding AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordate Medical Holding AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 Tommy Hedberg Other Other 2,917 11,668.00 SEK
2024-03-26 Anders Weilandt Other Buy 800,000 41,440.00 SEK
2024-03-26 Anders Weilandt Other Buy 200,000 10,540.00 SEK
2023-05-26 Anders Weilandt Other Buy 2,000,000 84,000.00 SEK
2023-05-26 Jan Hermansson Other Buy 750,000 31,500.00 SEK
2023-05-26 Nils Henrik Milton Rammer Other Other 350,000 14,700.00 SEK
2023-05-26 Caroline Brandberg Other Other 225,000 9,450.00 SEK
2023-05-26 Tommy Hedberg Other Buy 225,000 9,450.00 SEK
2023-01-09 Anders Weilandt Other Buy 3 2.10 SEK
2022-02-25 Anders Weilandt Other Buy 51,292 3,949,484.00 SEK

Peer Companies

LYSOGENE Logo
A former clinical-stage biotech that developed gene therapies for rare CNS diseases.
France
LYS
MaaT Pharma Logo
A clinical-stage biotech developing microbiome-based therapeutics for oncology.
France
MAAT
Matinas BioPharma Holdings, Inc. Logo
Biopharma firm developing therapeutics using its Lipid Nanocrystal (LNC) platform.
United States of America
MTNB
Matricelf Ltd. Logo
Develops autologous, patient-specific tissue implants for regenerative medicine.
Israel
MTLF
MAXCYTE, INC. Logo
A cell-engineering company with a platform for developing cell-based therapeutics.
United States of America
MXCT
Medicofarma Biotech Spolka Akcyjna Logo
R&D company developing innovative medicines, medical devices, and biotech products.
Poland
MDB
Medigene AG Logo
Develops TCR-guided immunotherapies for cancer; currently in insolvency proceedings.
Germany
MDG1
Medizen Humancare Inc Co., Ltd Logo
A research company specializing in genomic analysis for personalized healthcare.
South Korea
236340
Medpace Holdings, Inc. Logo
A global CRO providing Phase I-IV clinical development for biotech and pharma industries.
United States of America
MEDP
A clinical-stage biotech developing nanomedicines for oncology and diagnostics.
Malaysia
N/A

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.